Even before the FDA initiated its recent detente with obesity drug manufacturers (signaling potential approvals for Qnexa, Lorcaserin and others), the obesity treatment market was poised to go through a number of evolutionary phases as manufacturers — of drugs and devices — are working diligently to introduce, expand indications for and even phase out a range of products. The guarantor that these changes would take place is the growing demand for effective treatments as obesity incidence and prevalence grow worldwide and more data on its complications (diabetes, vascular disease, stroke, hypertension, etc.) emerge to validate the need for new treatment options.
Below is the outlook for the obesity market in the Americas (including the principal American markets of the U.S., Canada, Mexico and Brazil) for the different obesity drugs and devices on the market now, or expected to reach market during the forecast period.
Source: MedMarket Diligence, LLC; Report #S835.